Jubilant Pharmova Ltd
Ticker: JUBLPHARMA
Decent
68/100
☆ Add to Watchlist
Investing Reference
Price
1076.20
Market Cap
17046.66
Debt/Equity
0.4378
ROE %
14.398
PB
2.7324
Promoter %
47.676
Pledge %
0.000
1Y Rev Growth %
12.583
5Y Rev Growth %
4.182
NP Margin %
10.971
NP Margin 5Y Avg %
6.193
Trading Reference
1M Return %
-4.211
6M Return %
16.991
1Y Return %
-11.931
% Away 52W High
21.715
% Away 52W Low
34.190
Daily Volume
444676
Investment Verdict
Hold
Score 65/100 · Position size: 30%
Fundamentals are OK but not compelling. Maintain current position; avoid fresh adds.
Trading Verdict
Avoid
Score 31/100 · Position size: 0%
Momentum weak or trend adverse. Avoid trading at this point.
Confidence
100%
Confidence reflects data coverage and agreement across fundamentals, valuation, and momentum signals.
AI Probability Statement
Probability Statement
Jubilant Pharmova Ltd is likely to experience moderate upside potential as it approaches key resistance levels, with strong support observed at lower price points. The current volume trends suggest a bullish sentiment, indicating a potential upward movement in the medium term.
Upside Probability: 15% | Downside Probability: 10%
Probability estimates are technical-context statements, not investment advice.
More Options
A
Aditya Birla Lifestyle Brands Ltd
Aditya Birla Lifestyle Brands Ltd shows potential for growth but faces challenges in profitability and valuation metrics. Investors should be cautious and consider market conditions.
View details
G
Gabriel India Ltd
Gabriel India Ltd shows potential in a transitioning sector, but faces challenges in growth consistency and profitability metrics.
View details
D
Deepak Fertilisers and Petrochemicals Corp Ltd
The company shows potential for growth but faces several challenges that could impact its performance.
View details
V
Vinati Organics Ltd
Vinati Organics Ltd shows potential for growth with solid fundamentals, but investors should be cautious of execution risks and market volatility.
View details
V
Vedant Fashions Ltd
Vedant Fashions Ltd shows potential for growth in a favorable sector, but faces challenges in profitability and valuation metrics.
View details
V
Ventive Hospitality Ltd
Ventive Hospitality Ltd shows potential but faces significant challenges in profitability and market conditions, making it a risky investment.
View details
G
Gujarat State Petronet Ltd
Gujarat State Petronet Ltd shows decent potential with consistent growth and profitability metrics, but valuation concerns and execution risks should be monitored.
View details
U
UTI Asset Management Company Ltd
UTI Asset Management Company Ltd shows potential for growth, but faces challenges in profitability and competition.
View details
J
JM Financial Ltd
JM Financial Ltd shows potential but faces challenges in growth consistency and market sentiment.
View details
W
Whirlpool of India Ltd
Whirlpool of India Ltd shows decent potential, but faces challenges in profitability and execution risks.
View details
C
Concord Biotech Ltd
Concord Biotech Ltd shows potential for growth but faces challenges in valuation and execution risks.
View details
C
Caplin Point Laboratories Ltd
Caplin Point Laboratories Ltd shows potential for growth but faces challenges in profitability and valuation metrics.
View details
T
Triveni Turbine Ltd
Triveni Turbine Ltd shows potential in a growing sector with decent financial metrics, but faces challenges in profitability consistency and valuation concerns.
View details
J
JBM Auto Ltd
JBM Auto Ltd shows potential in a growing sector, but faces challenges in execution and valuation.
View details
T
Travel Food Services Ltd
Travel Food Services Ltd faces significant challenges in growth and profitability, making it a risky investment at this time.
View details
A
Aditya Infotech Ltd
Aditya Infotech Ltd shows potential in a growing sector but faces challenges in consistent growth and profitability. Caution is advised due to execution risks and market sentiment.
View details
Business Overview
Jubilant Pharmova Ltd is a leading global pharmaceutical and biotechnology company based in India, focusing on innovative solutions in healthcare. It caters to a diverse clientele, including hospitals, healthcare providers, and pharmaceutical companies, delivering high-quality products and services that enhance patient care. The company plays a crucial role in addressing critical health challenges, making it a trusted partner in the healthcare ecosystem. With a commitment to research and development, Jubilant Pharmova is poised for sustainable growth and long-term value creation.
- Global leader in pharmaceuticals and biotechnology
- Focus on innovative healthcare solutions
- Serves hospitals and healthcare providers
- Strong commitment to research and development
- Addresses critical health challenges
- Sustainable growth and long-term value creation
Investment Thesis
Jubilant Pharmova Ltd presents a compelling investment opportunity due to its strong promoter credibility, robust growth in digital services, and attractive valuation compared to peers. The company's strategic focus on innovation and expansion positions it well for future growth, making it a valuable addition to any portfolio.
- Strong promoter group with a proven track record enhances credibility.
- Significant growth potential in digital services sector.
- Attractive valuation metrics compared to industry peers.
- Strategic investments in R&D driving innovation.
- Resilient business model with diversified revenue streams.
Opportunity vs Risk
Opportunities
- Strong growth in healthcare sector
- Expansion in international markets
- Innovative product pipeline
- Strategic partnerships and collaborations
- Rising demand for generics
Risks ⚠️
- Regulatory challenges in pharmaceuticals
- Intense competition in the market
- Currency fluctuations impacting profits
- Supply chain disruptions
- R&D costs may escalate
Peer Perspective
Jubilant Pharmova Ltd trades at a discount compared to peers like Sun Pharma and Dr. Reddy's, primarily due to margin pressures. A stabilization in margins could trigger a rerating, aligning its valuation with industry standards.
Future Outlook
Jubilant Pharmova Ltd is well-positioned for growth, driven by its innovative pipeline and expanding market presence. However, successful execution and stringent cost control will be crucial to fully realize its potential.
AI FAQs for Retail Users
- Q: What does Jubilant Pharmova Ltd do?A: Jubilant Pharmova Ltd is a pharmaceutical and life sciences company focusing on drug development and manufacturing.
- Q: Is Jubilant Pharmova Ltd a good investment?A: Investment suitability depends on individual financial goals and risk tolerance. Research and consult a financial advisor.
- Q: What are the recent developments in Jubilant Pharmova Ltd?A: Recent developments include new product launches and collaborations in the pharmaceutical sector.
- Q: How can I buy shares of Jubilant Pharmova Ltd?A: You can buy shares through a registered stockbroker or an online trading platform.
- Q: What are the risks of investing in Jubilant Pharmova Ltd?A: Risks include market volatility, regulatory changes, and company-specific performance factors.
📊 Stock Investment Checklist (100 Points)
Jubilant Pharmova Ltd • Updated: 2025-09-17 02:57:09
-
10BusinessHighPharmaceutical sector is essential and growing, but competition is intense.
-
10GrowthHighConsistent revenue growth, but profit margins are under pressure.
-
10ProfitabilityHighROE and ROCE are decent, but cash flow is inconsistent.
-
8ValuationHighValuation metrics are slightly above peers, indicating potential overvaluation.
-
7BalanceHighModerate debt levels, but liquidity ratios are satisfactory.
-
6GovernanceGoodPromoter holding is stable, but some concerns over pledging.
-
5DriversGoodGrowth drivers exist, but execution risks are significant.
-
5TechnicalsGoodMarket sentiment is mixed, with low liquidity.
Final Score & Verdict
Score 68 / 100
• Decent
Jubilant Pharmova Ltd shows potential for growth but faces challenges in profitability and valuation. Investors should be cautious.
AI Confidence Score
Instead of just “overall score,” broken into categories:
- Business Strength: 75/100
- Growth Potential: 70/100
- Profitability: 65/100
- Governance: 60/100
- Market Confidence: 68/100